PMID- 35604203
OWN - NLM
STAT- MEDLINE
DCOM- 20230331
LR  - 20230331
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Linking)
VI  - 19
IP  - 2
DP  - 2023 Apr
TI  - Safety and effectiveness of transdermal buprenorphine in cancer pain: An 
      observational study in Taiwan (SOOTHE).
PG  - e45-e53
LID - 10.1111/ajco.13772 [doi]
AB  - AIM: Buprenorphine is one of the strongest opioids used for the relief of cancer 
      pain. This study aims to evaluate the real-world clinical experiences of 
      transdermal buprenorphine used in moderate to severe cancer pain in the Asian 
      population. METHODS: This is an open-labeled, multicenter, 4-week observational 
      study. Stable cancer pain patients who decided to switch the previous opioid to 
      transdermal buprenorphine will be enrolled in this study. The safety and 
      effectiveness were observed and collected. Pain assessment was performed using a 
      numerical rating scale by the investigators and the Brief Pain Inventory Short 
      Form (BPI-SF) by the patient. The safety profiles included concomitant 
      medications and adverse events (AEs). RESULTS: A total of 83 patients were 
      enrolled in this study. The global pain scores in the BPI, as well as the four 
      individual pain parameters (worst, least, average, and right now), showed a 
      continued decrease (p < .05) from week 2 to week 4. Significant improvements were 
      observed in normal work activities, relations with other people, sleep, enjoyment 
      of life, and global BPI pain interference score on week 4. Pain assessments 
      conducted by investigators demonstrated significant, continuous improvements 
      during the study periods. In addition, transdermal buprenorphine demonstrated 
      good safety/tolerability with limited drug-related AEs in the Asian population 
      with cancer pain. CONCLUSION: This study demonstrated that transdermal 
      buprenorphine in the Asian population has good safety profiles and continued 
      improvements in pain relief, sleep, and pain interferences. Transdermal 
      buprenorphine can be an effective and convenient option as a transdermal opioid 
      for patients with moderate to severe cancer pain in Taiwan. (NCT Number: 
      NCT04315831).
CI  - (c) 2022 John Wiley & Sons Australia, Ltd.
FAU - Huang, Tai-Lin
AU  - Huang TL
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Huang, Yen-Min
AU  - Huang YM
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Hou, Min-Mo
AU  - Hou MM
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Lu, Chang-Hsien
AU  - Lu CH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Chiayi Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Chao, Tsu-Yi
AU  - Chao TY
AD  - Department of Hematology/Oncology, Shuang Ho Hospital, Zhonghe District, New 
      Taipei City, 235, Taiwan.
FAU - Chiu, Tai-Jan
AU  - Chiu TJ
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Chang, Yueh-Shih
AU  - Chang YS
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Lin, Sheng-Hao
AU  - Lin SH
AD  - Department of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan.
FAU - Lin, Ching-Hsiung
AU  - Lin CH
AD  - Department of Chest Medicine, Changhua Christian Hospital, Changhua, 500, Taiwan.
FAU - Chen, Yen-Hao
AU  - Chen YH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Wang, Cheng-Hsu
AU  - Wang CH
AUID- ORCID: 0000-0002-7248-3983
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Keelung Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Chen, Jen-Shi
AU  - Chen JS
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
FAU - Shen, Wen-Chi
AU  - Shen WC
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Linkou Chang 
      Gung Memorial Hospital, and Chang Gung University, Taoyuan, 333, Taiwan.
LA  - eng
SI  - ClinicalTrials.gov/NCT04315831
GR  - Taiwan Mundipharma Pharmaceuticals Ltd./
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20220522
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
RN  - 0 (Analgesics, Opioid)
RN  - 40D3SCR4GZ (Buprenorphine)
SB  - IM
MH  - Humans
MH  - Analgesics, Opioid/adverse effects
MH  - *Cancer Pain/drug therapy
MH  - Taiwan
MH  - Pain/etiology/chemically induced
MH  - *Buprenorphine/adverse effects
MH  - *Neoplasms/complications/drug therapy
OTO - NOTNLM
OT  - anxiety/depression
OT  - cancer pain
OT  - pain control
OT  - transdermal buprenorphine
EDAT- 2022/05/24 06:00
MHDA- 2023/03/31 06:42
CRDT- 2022/05/23 09:07
PHST- 2021/07/21 00:00 [received]
PHST- 2022/02/09 00:00 [accepted]
PHST- 2023/03/31 06:42 [medline]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/23 09:07 [entrez]
AID - 10.1111/ajco.13772 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2023 Apr;19(2):e45-e53. doi: 10.1111/ajco.13772. Epub 2022 
      May 22.